Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus death

Journal of the American Medical Directors Association

Volumn 11, Issue 8, 2010, Pages 584-591

  Curtis, Jeffrey R ^a   Arora, Tarun ^b   Matthews, Robert S ^b   Taylor, Allison ^b   Becker, David J ^b   Colon Emeric, Cathleen ^c   Kilgore, Meredith L ^b   Morrisey, Michael A ^b   Saag, Kenneth G ^a,b   Safford, Monika M ^d   Warriner, Amy ^b   Delzell, Elizabeth ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DUKE UNIVERSITY   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; COMORBIDITY; DEATH; FEMALE; FOREARM FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 77957219858     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2009.12.004     Document Type: Article

References (36)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. 2008. Available at: Accessed April 10, 2008. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf.
2. Burge R., Dawson-Hughes B., Solomon D.H., et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
3. Curtis J.R., Carbone L., Cheng H., et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008, 23:1061-1067.
4. Quick Reference Information: Medicare Preventive Services. The Medicare Learning Network (MLN). 2007, p 243. Available at: Accessed March 19, 2008. http://www.cms.hhs.gov/MLNProducts/downloads/mps_guide_web-061305.pdf.
5. State of Health Care Quality 2006. Washington, DC: National Committee for Quality Assurance; 2006 [updated 2006; cited]; Available at: Accessed January 13, 2010. http://www.ncqa.org/Portals/0/Publications/Resource%20Library/SOHC/SOHC_2006.pdf.
6. Giangregorio L., Papaioannou A., Cranney A., et al. Fragility fractures and the osteoporosis care gap: An international phenomenon. Semin Arthritis Rheum 2006, 35:293-305.
7. Curtis J.R., McClure L.A., Delzell E., et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009, 24:956-962.
8. Mudano A., Casebeer L., Patino F., et al. Racial disparities in osteoporosis prevention in a managed care population. South Med J 2003, 96:445-451.
9. Mikuls T.R., Saag K.G., George V., et al. Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol 2005, 32:870-875.
10. Hodgson S.F., Johnston C.C. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. Endocrine Practice 1996, 2:155-181.
11. Qaseem A., Snow V., Shekelle P., et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 149:404-415.
12. Centers for Medicare and Medicaid Services. Physician Quality Reporting Initiative. Available at: Accessed June 1, 2009. http://www.cms.hhs.gov/pqri.
13. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
14. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
15. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 1999, 282:1344-1352.
16. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
17. Brenneman S.K., Barrett-Connor E., Sajjan S., et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006, 21:809-816.
18. Cockerill W., Lunt M., Silman A.J., et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004, 15:113-119.
19. Penrod J.D., Litke A., Hawkes W.G., et al. The association of race, gender, and comorbidity with mortality and function after hip fracture. J Gerontol A Biol Sci Med Sci 2008, 63:867-872.
20. Curtis J.R., Mudano A.S., Solomon D.H., et al. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009, 47:69-72.
21. Ray W.A., Griffin M.R., Fought R.L., Adams M.L. Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992, 45:703-714.
22. Baron J.A., Lu-Yao G., Barrett J., et al. Internal validation of Medicare claims data. Epidemiology 1994, 5:541-544.
23. Dawson-Hughes B., Tosteson A.N., Melton L.J., et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008, 19:449-458.
24. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
25. Kanis J.A., Oden A., Johnell O., et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004, 15:108-112.
26. Abrahamsen B., van Staa T., Ariely R., et al. Excess mortality following hip fracture: A systematic epidemiological review. Osteoporos Int 2009, 20:1633-1650.
27. Center J.R., Bliuc D., Nguyen T.V., Eisman J.A. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007, 297:387-394.
28. von Friesendorff M., Besjakov J., Akesson K. Long-term survival and fracture risk after hip fracture: A 22-year follow-up in women. J Bone Miner Res 2008, 23:1832-1841.
29. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001, 285:2750-2756.
30. Freemantle N., Cleland J., Young P., et al. beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999, 318:1730-1737.
31. Lippuner K. Medical treatment of vertebral osteoporosis. Eur Spine J 2003, 12:S132-S141.
32. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., Wu A.W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005, 294:716-724.
33. van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests. Lancet 2006, 367:550-551.
34. Quan H., Parsons G.A., Ghali W.A. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002, 40:675-685.
35. Luthi J.C., Troillet N., Eisenring M.C., et al. Administrative data outperformed single-day chart review for comorbidity measure. Int J Qual Health Care 2007, 19:225-231.
36. FRAX. Who Fracture Risk Assessment Tool. Available at: Accessed May 31, 2008. http://shef.ac.uk/FRAX.